Clinical Trial Detail

NCT ID NCT03807063
Title Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Washington
Indications

chronic myelomonocytic leukemia

myelodysplastic/myeloproliferative neoplasm

myelodysplastic syndrome

chronic myeloid leukemia

acute myeloid leukemia

chronic lymphocytic leukemia

acute lymphoblastic leukemia

myeloproliferative neoplasm

Therapies

Rimiducid

BPX-501

Age Groups: adult child senior

No variant requirements are available.